ALSO READAstraZeneca Pharma India Q4 net loss at Rs 2.87 cr Astrazeneca Pharma India reports standalone net loss of Rs 2.88 crore in the March 2017 quarter Bitter pill for AstraZeneca Pharma after reverse turnaround in Q4 AstraZeneca Pharma India to launch cancer drug - Osimertinib Tablet Pharma stocks witness selling pressure; fall up to 5 pc
From Drug Controller General of IndiaAstrazeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC of Budesonide 320 g +Formoterol Fumarate Dihydrate 9 g inhalation powder.
FDC of Budesonide 320 g + Formoterol Fumarate Dihydrate 9 g inhalation powder (Symbicort Turbuhaler 320/9 g) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)